Non-cytotoxic blocking antibodies and suppressor cells induced by donor-specific transfusions in healthy volunteers and potential kidney transplant recipients

Horuzsko, Anatolij; Gyódi, É; Réti, Marienn; K, Onody; Perner, F.; Kassay, MIKLóS; Petrányi, G

doi:10.1016/0165-2478(90)90134-c

Cited by 7 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…74 DST induces the differentiation of suppressor cells, production of anti-idiotypic antibodies, and the appearance of nonspecific, non-cytotoxic antibodies, which may participate in the cell-mediated immune suppression of alloimmune reactivity. 75 Although the role of CD4þ regulatory cells in downregulating the alloreactive cytotoxic T-lymphocyte (CTL) response is not clear, they might produce large amounts of Th2-like cytokines such as IL-10, which enhances graft tolerance. 70 Microchimerism with the concomitant persistence of soluble donor HLA antigen is considered to be the most important mechanism by which DST modulates the immune system.…”

Section: Experimental Studiesmentioning

confidence: 99%

Role of Blood Transfusion in Transplantation: A Review

Siemionow¹,

Ağaoğlu²

2005

J reconstr Microsurg

View full text Add to dashboard Cite

The ultimate goal of transplantation immunology is induction of donor-specific tolerance without the need for chronic immunosuppression. A number of strategies have been used to induce tolerance, including donor-specific blood transfusion (DST). A large number of experimental and clinical studies have evaluated the ability of DST to induce tolerance in solid organ transplantation. In contrast, a limited number of experimental studies have been reported evaluating the effect of DST in induction of tolerance in composite tissue allograft transplants. DST applications include cadaveric and living-related graft recipients in humans, leading to achievement of microchimerism. Although the mechanism of action is still uncertain, microchimerism with the concomitant persistence of soluble donor HLA antigen is considered to be the most significant contributing factor. In this article, the experimental and clinical applications, as well as the immunomodulatory mechanism of DST, are reviewed.

show abstract

Section: Experimental Studiesmentioning

confidence: 99%

Role of Blood Transfusion in Transplantation: A Review

Siemionow¹,

Ağaoğlu²

2005

J reconstr Microsurg

View full text Add to dashboard Cite

show abstract

“…Initially, it was thought that the beneficial immu nosuppressive effect can only be induced with blood com ponents containing a suitable number of leukocytes. This theory was supported by clinical data that demonstrated that the protective immune response would not develop in pa tients who received leukocyte-poor blood products (frozen and thawed or filtered red blood cell) [116,117], It is now evident, however, that immunosuppressive regulation can also be induced by a purified platelet concentrate containing only a small number (< lx 10*') of leukocytes [118][119][120]. In addition to the appropriate matching rate of MHC antigens between the donor and the recipient, other alloantigeneic systems also affect the suppressive regulation.…”

Section: The Beneficial ' Effect O F Transfusion On Transplantation Amentioning

confidence: 64%

Immunologic Consequences of Blood Transfusion and Their Clinical Manifestations

Petranyi

Réti

Harsányi

et al. 1997

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Aspects of clinical immunology, in the context of transfusion medicine, became highlighted in the last decade as a consequence of the accelerating expansion of basic immunology, immunogenetics and molecular biology. In addition sophisticated new technologies, which were capable of producing pure and safe blood products, attracted more attention to research and monitor the consequences of transfusion. These technologies also had obvious effects on supportive hematological therapy. The transfusion of blood components follows the rules of organ transplantation: when there is a mismatch between the donor and the recipient, the transfusion has the potential to induce various kinds of immune response against alloantigens. Antigen-compatible transfusions that involve major and rare blood groups are in almost all cases mismatched with respect to various polymorphic systems expressed on the cellular blood components. These include histocompatibility leukocyte antigens (HLA), tissue-specific and differentiation alloantigens, and, in the case of plasma, immunoglobulins, complement components, heat shock proteins, and shedded soluble membrane alloantigens. Clinical manifestations of alloimmune responses are typically deleterious. For example, immediate antigen-antibody binding and its consequences as secondary activations are paralleled by the nonhaemolytic febrile reaction, HLA sensitization can lead to a state of platelet refractoriness and inconvenient clinical symptoms. In certain immunogenetic situations and in immunodeficient patients graft-versus-host disease can be induced by blood products that contain live lymphocytes. Leukocyte filtration techniques are widely used to avoid most but not all of these harmful side effects of blood component therapy. In contrast to these harmful side effects in certain immunogenetic conditions, alloantigens that are expressed on various blood products can elicit an advantageous suppression of the immune response in the recipient. In the context of kidney transplantation this is termed the ‘beneficial transfusion effect’, and typically results in the prolongation of the graft’s survival. In cases of recurrent habitual abortion and IgG therapy associated with certain autoimmune diseases, immunization with leukocytes specifically takes advantage of this phenomenon. To date the beneficial transfusion effect is not fully understood. In certain cases of malignancies or gastrointestinal surgeries this suppression of immune regulation that is induced by transfusion can worsen the clinical state either by permitting the spread of the tumor or by allowing severe infections to proceed unchecked. In conclusion it is imperative to monitor the immunological consequences of transfusion in order to deter the disadvantageous side effects. Taking advantage of the ‘beneficial transfusion effect’ may also provide a new means for immune therapy using the various blood products.

show abstract

Cellular and humoral suppression in transplantation

Petrányi

1992

Immunology Today

View full text Add to dashboard Cite

Non-cytotoxic blocking antibodies and suppressor cells induced by donor-specific transfusions in healthy volunteers and potential kidney transplant recipients

Cited by 7 publications

References 11 publications

Role of Blood Transfusion in Transplantation: A Review

Role of Blood Transfusion in Transplantation: A Review

Immunologic Consequences of Blood Transfusion and Their Clinical Manifestations

Cellular and humoral suppression in transplantation

Contact Info

Product

Resources

About